We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy (DM200-101)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00638716
First Posted: March 19, 2008
Last Update Posted: June 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
ConjuChem
  Purpose

This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study.

The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.


Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: CJC-1134-PC Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

Resource links provided by NLM:


Further study details as provided by ConjuChem:

Primary Outcome Measures:
  • Reduction of HbA1c From Baseline [ Time Frame: Screening and Day 85 ]
    Change from Baseline


Secondary Outcome Measures:
  • Reduction in FPG From Baseline [ Time Frame: Screening and Day 85 ]
    Change from Baseline

  • Reduction in Fasting Body Weight From Baseline [ Time Frame: Screening and Day 85 ]
    Change from Baseline


Enrollment: 122
Study Start Date: February 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
12 weekly doses of 1.5 mg CJC-1134-PC
Drug: CJC-1134-PC
1.5 or 2.0 mg CJC-1134-PC
Experimental: 2
4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
Drug: CJC-1134-PC
1.5 or 2.0 mg CJC-1134-PC
Placebo Comparator: 3
12 weekly doses of placebo
Drug: Placebo
Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Major Inclusion Criteria:

  • BMI: 27 to 45 kg/m2
  • Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator
  • Stable life-style, i.e. diet & physical activity, as determined by the Investigator
  • Stable metformin daily dose ≥1000 mg for at least 3 months
  • Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00638716


Locations
Canada, Quebec
ConjuChem Biotechnologies Inc.
Montreal, Quebec, Canada, H2X 3Y8
Sponsors and Collaborators
ConjuChem
  More Information

Responsible Party: ConjuChem
ClinicalTrials.gov Identifier: NCT00638716     History of Changes
Other Study ID Numbers: DM200-101
First Submitted: March 13, 2008
First Posted: March 19, 2008
Results First Submitted: May 2, 2017
Results First Posted: June 2, 2017
Last Update Posted: June 2, 2017
Last Verified: May 2017

Keywords provided by ConjuChem:
Type 2 Diabetes Mellitus, incretins, GLP-1, HbA1c, metformin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs


To Top